haematologica
Journal of the Ferrata Storti Foundation

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma"

by Yushan Jin, Yuan Fang and Yao Yao

Received: July 15, 2026.
Accepted: July 16, 2026.

Citation: Yushan Jin, Yuan Fang and Yao Yao. Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma". Haematologica. 2026 July 23. doi: 10.3324/haematol.2026.301607 [Epub ahead of print]

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.
E-publishing of this PDF file has been approved by the authors.
After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval, the final version of the manuscript will then appear in a regular issue of the journal.
All legal disclaimers that apply to the journal also pertain to this production process.

RETRACTED

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma"

Yushan Jin[1,2], Yuan Fang[1 *], Yao Yao[1*],

1 The First Affiliated Hospital of Dalian Medical University, Dalian, China

[2] College of Laboratory Medicine, Dalian Medical University, Dalian, China

*** Corresponding authors:**

Yuan Fang , The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China, E-mail: 17709810355@163.com

Yao Yao, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China, E-mail: Yix89@outlook.com

RETRACTED

Authors' contributions

All authors contributed equally to the conception and drafting of the manuscript and approved the submitted version.

Disclosure

The authors declare no conflict of interest.

Ortiz-Maldonado V and colleagues address an important question in hematology: A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma. [1] The article is valuable because it tackles a clinically recognizable problem and provides a useful basis for discussion. The key issue, however, is whether durable responses after dose-dense CD19 CAR T-cell therapy are attributable to dosing strategy rather than patient selection, disease biology, or supportive-care differences. This distinction matters because readers may otherwise move too quickly from an interesting observation to a clinical or methodological conclusion that the present evidence does not fully establish. We therefore believe the article should be read not only for its main result, but also for the assumptions that determine how far that result can travel.

The first issue is that dose density is a plausible determinant of CAR T-cell expansion, but lymphoma burden, prior therapies, bridging treatment, and inflammatory status can strongly influence both efficacy and toxicity. The second is that the absence of increased toxicity is encouraging, yet cytokine-release syndrome, neurotoxicity, cytopenias, infections, and delayed immune recovery should be interpreted alongside response durability. [2], [3] These concerns do not diminish the contribution of the study, but they define the conditions under which the findings can be applied. A strong letter should make this boundary visible, because the most important risk for readers is not that the result is uninteresting, but that its practical meaning is broader than the data can support. In this sense, the central question is not whether the work is useful; it is what exact decision, hypothesis, or future study the work can legitimately support.

This distinction has practical consequences for interpretation. If the study is read as definitive, readers may focus on the headline conclusion and overlook design features that shape the estimate, such as patient selection, timing of measurement, endpoint definition, missing data, operator behavior, or treatment pathway after enrollment. If it is read as a carefully bounded contribution, however, the same findings become more useful because they identify where the evidence is strong and where replication or refinement is still required. That framing is especially important for studies likely to influence clinical language before they change clinical practice.

A third issue is that future studies should prespecify pharmacokinetic and pharmacodynamic readouts that connect dose schedule to CAR expansion, persistence, and exhaustion. [4] The next study should therefore be designed around a small number of prespecified questions: which subgroup is most likely to benefit from the proposed interpretation, which outcome should be considered decisive, and what level of follow-up, technical quality, or data completeness would make the conclusion reproducible. Answering these questions would help move the field from an interesting report to a usable clinical or methodological standard. Such a design would also make negative or neutral findings more informative, because it would show whether the original signal fails generally or only under specific biological, technical, or operational conditions.

The findings should also be discussed with attention to negative and neutral results. A focused letter is most useful when it protects readers from a one-directional interpretation of promising data. If the reported strategy performs well only under selected conditions, that

RETRACTED

limitation should be visible early. If the observed effect is clinically attractive but operationally difficult, implementation barriers should be treated as part of the evidence rather than as a secondary concern. This is not a conservative posture for its own sake. It is a way to keep promising results actionable without turning them into recommendations before the necessary comparative or external evidence exists.

We would therefore encourage future work to report the elements that determine transportability. For clinical studies, these include baseline risk, co-interventions, follow-up intensity, competing events, safety, and patient-centered outcomes. For biomarker, registry, artificial-intelligence, or methodological studies, they include calibration, missingness, data provenance, annotation quality, temporal drift, and external validation. Making these elements explicit would allow readers to distinguish a robust finding from a finding that is promising but context-dependent.

In summary, A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma is a meaningful contribution to the literature. [1] The strategy is promising, but it should be presented as a testable dosing hypothesis rather than definitive evidence that intensification alone improves outcomes. Its greatest value lies in opening a practical discussion about how the reported evidence should be used, verified, and communicated. Clearer boundaries can strengthen, rather than weaken, the impact of a well-conducted study, because they show readers exactly what should change now and what still requires confirmation.

RETRACTED

Reference

[1] Ortiz-Maldonado V, Liang EC, Huang JJ, et al. A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma. Haematologica. 2026 July 2. Doi: 10.3324/haematol.2025.300321. [Epub ahead of print]

[2] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

[3] Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer. 2022;10(12):e005678.

[4] Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.

RETRACTED